StockNews.AI
CSBR
StockNews.AI
161 days

Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

1. CSBR reports 42% revenue increase, reaching $17M in Q3 FY2025. 2. Signed data licensing deal valued up to $8M, indicating growth potential.

3m saved
Insight
Article

FAQ

Why Bullish?

The substantial revenue increase and new data licensing deal suggest strong financial health. Historically, similar growth announcements have led to positive stock performance.

How important is it?

The first major data licensing deal and revenue growth are key indicators of CSBR's market expansion and profitability.

Why Short Term?

The immediate impact from Q3 results and licensing deal is likely to boost investor confidence rapidly.

Related Companies

ONCTCLRBMDGL
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025. Third Quarter and Recent Highlights: Total revenue increased 42% to $17.0 million Gross profit of $10.4 million; gross margin of 61% Net income of approximately $4.5 million Adjusted EBITDA of $5.2 million Signed first data licensing deal worth up to $8.0 million Hired Matt Newman, Executive Vice President and General Manager, to lead and expand the development of Champions' data licensing platform Year to Date Highlights: Total revenue increased 23% to $44.6 million Gross profit of $23.5 million; gross margin of 53% Net income of $6.5 million Adjusted EBITDA of $8.3 million Ronnie Morris, CEO of Champions, commented, "Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform.

Related News